41
Mid-Myocardial Septal Substrate for Ventricular Tachycardia in Nonischemic Cardiomyopathy Haris M. Haqqani MBBS(Hons) PhD FRACP FCSANZ FHRS FACC Associate Professor of Medicine, The University of Queensland Senior Consultant Electrophysiologist, The Prince Charles Hospital Brisbane, Australia

Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

  • Upload
    others

  • View
    2

  • Download
    0

Embed Size (px)

Citation preview

Page 1: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

Mid-Myocardial Septal Substrate

for Ventricular Tachycardia in

Nonischemic Cardiomyopathy

Haris M. HaqqaniMBBS(Hons) PhD FRACP FCSANZ FHRS FACC

Associate Professor of Medicine, The University of Queensland

Senior Consultant Electrophysiologist, The Prince Charles Hospital

Brisbane, Australia

Page 2: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

Disclosures

Company Name Relationship

Biosense Webster Research grant

Speaking honoraria

Boston Scientific Scientific advisory board

Speaking honoraria

Medtronic Scientific advisory board

Speaking honoraria

Abbott Speaking honoraria

The presenter has received financial support from the

organizations identified below for the relationships listed:

KHRS Scientific Sessions 2018, Seoul8 June 2018 2

Page 3: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

Usual pattern of

macroscopic basolateral

endocardial scar in NICM

Hsia, Marchlinski Circ 2003

Soejima, Stevenson JACC 2004

Waller et. al. AJC 1998

KHRS Scientific Sessions 2018, Seoul8 June 2018 3

Page 4: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

LV

RV

Periannular Endocardial ScarringPeriannular Low Voltage Area

LV

RV

>1.5 mV

<0.5 mV

Courtesy of

Dr Marchlinski

Pathologic

correlationmitral

annulus

mitral

annulus

tricuspid

annulus

tricuspid

annulus

PA view

PA view

KHRS Scientific Sessions 2018, Seoul8 June 2018 4

Page 5: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

Basal lateral (56.7 ± 33.1 cm2 ) confluent EPI

scar (< 1.0mV) away from coronaries

Versus 22.9 ± 32.4 cm2 ENDO scar

Electrogram Characteristics

- Wide Egms > 80ms - 27.5%

- Split Egms – 33.0%

- Late Potentials – 25.8%

- Wide, Split or Late - 50%

Cano, Marchlinski et al JACC 2009

>1.0 mV

<0.5 mV

Epicardial substrate in NICM

KHRS Scientific Sessions 2018, Seoul8 June 2018 5

Page 6: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

KHRS Scientific Sessions 2018, Seoul8 June 2018 6

What about

NICM patients

who don’t have

this typical

pattern of

basolateral

involvement?

Haqqani, Kalman, Morton

et. al. HRS 2008

Page 7: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

Haqqani, Marchlinski et. al. HRJ 2011KHRS Scientific Sessions 2018, Seoul8 June 2018 7

266 consecutive UPenn

NICM* pts with SMVT

undergoing VT ablation

(1999 to 2010)

31/266 (11.3%) patients

had isolated septal

substrate on EAM and/or

imaging with no lateral

wall involvement

*Excluded secondary causes of

NICM including sarcoid, VHD,

ACHD, HCM, EtOH, TMC etc.

Page 8: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

Haqqani, Marchlinski et. al. HRJ 2011KHRS Scientific Sessions 2018, Seoul8 June 2018 8

Baseline characteristics n = 31

Age 59 ± 12 years

Males 26 (84%)

LV ejection fraction 30 ± 14%

LV EDD 62 ± 11mm

Amiodarone use 24 (77%)

LBBB 10 (32%)

Complete AV block 8 (26%)

RV / BiV pacing 6 (19%) / 6 (19%)

ICD in situ 26 (84%)

Prior procedures 10 (32%) – 1.7

Page 9: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

Haqqani, Marchlinski et. al. HRJ 2011KHRS Scientific Sessions 2018, Seoul8 June 2018 9

Endocardial Mapping n = 31

LV endocardial points 305 ± 121

Septal bipolar voltage <1.5mV 22/31 (71%)*

LV area of bipolar low voltage 63 ± 41cm2

Prop. of LV with low Bi voltage 26 ± 13%

RV mapping performed 17 (57%)

RV endocardial points 188 ± 130

RV area of bipolar low voltage 23 ± 27cm2

Proportion of RV with low voltage 14 ± 16%

*Of the 9 patients with

normal bipolar voltage,

all had extensive septal

areas of low unipolar

voltage (<8.3mV) with

lateral wall spared in all

(80 ± 36cm2 or 40 ±

16% of LV surface area)

Page 10: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

KHRS Scientific Sessions 2018, Seoul8 June 2018 10Haqqani, Marchlinski et. al. HRJ 2011

Page 11: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

Haqqani, Marchlinski et. al. HRJ 2011KHRS Scientific Sessions 2018, Seoul8 June 2018 11

Epicardial mapping

performed in 14 (45%)

9 patients had a

normal epicardial

substrate map

5 patients had

patchy fractionation

at LV summit

CMR performed in 9

patients (29%) [ICDs]

8 patients had

septal DGE

Page 12: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

KHRS Scientific Sessions 2018, Seoul8 June 2018 12

33 yo man

with NICM,

SMVT and

LVEF 40%

Haqqani, Marchlinski et. al. HRJ 2011

Page 13: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

Haqqani, Marchlinski et. al. HRJ 2011KHRS Scientific Sessions 2018, Seoul8 June 2018 13

VT characteristics n = 151

Cycle length 396 ± 90ms

VT QRS duration 186 ± 34ms

Mappable VTs 54 (36%)

LBBB configuration 57 (38%)

Inferior limb lead discordance 24 (16%)

V2 transition pattern break 26 (17%)

Page 14: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

KHRS Scientific Sessions 2018, Seoul8 June 2018 14Haqqani, Marchlinski et. al. HRJ 2011

Page 15: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

V2

V1

HisTricuspid

valve

LCC

PA

RVOT

RCC RCA

LCA

NCCLAA

Mitral

valve

Precordial transition

‘pattern break’

Adapted from

Haqqani et. al.

JCE 2009Image courtesy

of Dr SY Ho

V1V2

V3

V4

V5

V6

I

II

III

aVR

aVL

aVF

V1

V6

V3

V4

V6

V5

V1

KHRS Scientific Sessions 2018, Seoul8 June 2018 15

V2

Page 16: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

Hayashi et. al. JCE 2017KHRS Scientific Sessions 2018, Seoul8 June 2018 16

Page 17: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

Haqqani, Marchlinski et. al. HRJ 2011KHRS Scientific Sessions 2018, Seoul8 June 2018 17

VT ablation results n = 50

Acute success 33 (66%)

Partial success 10 (20%)

Failure 7 (14%)

Complete AV block 5 (10%)*

New LBBB 2 (4%)

* Including during

septal transcoronary

ethanol ablation in 1

Complications n = 50

LAD spasm 1

Pericardial bleeding during

epicardial access

1

Cardiogenic shock 1

Late outcomes n = 31

Median follow up 12 mo

VT recurrence 10 (32%)

Death 8 (26%)

Heart transplant 5 (16%)

Page 18: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

KHRS Scientific Sessions 2018, Seoul Betensky et. al. Circ AE 20138 June 2018 18

Gp 1: n=14 with

no septal scar

Gp 2: n=26 with

septal scar

Page 19: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

KHRS Scientific Sessions 2018, Seoul Betensky et. al. Circ AE 20138 June 2018 19

Page 20: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

KHRS Scientific Sessions 2018, Seoul Oloriz et. al. Circ AE 20148 June 2018 20

87 idiopathic NICM

patients with SMVT

undergoing VT RFA

44 patients had

predominant

anteroseptal

unipolar scar

distribution

43 patients had

predominant

inferolateral

unipolar scar

distribution

• AS substrate

patients had more

endocardial

unipolar low

voltage (41 vs

9cm2)

• Left inferior axis

VT predicted AS

substrate

(PPV=100%)

• Right superior

axis VT predicted

IL substrate

(PPV=89%)

Page 21: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

KHRS Scientific Sessions 2018, Seoul8 June 2018 21Oloriz et. al. Circ AE 2014

Page 22: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

Oloriz et. al. Circ A&E 2014KHRS Scientific Sessions 2018, Seoul8 June 2018 22

Page 23: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

SR ECG

features of

AS vs. IL

substrate

Oloriz et. al.

Circ A&E 2014KHRS Scientific Sessions 2018, Seoul8 June 2018 23

Page 24: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

Clear association

with outcome

Oloriz et. al. Circ A&E 2014KHRS Scientific Sessions 2018, Seoul8 June 2018 24

Page 25: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

Non-idiopathic NICM case

• 35yo man

• short history of palpitations, cough, dyspnea and

syncope secondary to VT

• ECG: SR with normal conduction

• LVEF 35% ; normal coronary angiogram

• bilateral perihilar and mediastinal adenopathy

• PET: extensive RV and septal FDG uptake

consistent with sarcoidosis

• i/o dcICD and Rx glucocorticoids and HF therapy

• represented with ongoing appropriate ICD shocks

for MMVT despite treatment with amiodarone and

mexilitene

KHRS Scientific Sessions 2018, Seoul8 June 2018 25

Page 26: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

KHRS Scientific Sessions 2018, Seoul8 June 2018 26

Page 27: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

VT 1 VT 2 VT 4VT 3 VT 5 VT 6 VT 7

KHRS Scientific Sessions 2018, Seoul8 June 2018 27

Page 28: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

>1.5 mV

<0.5 mV

Bipolar

>1.5 mV

<0.5 mV

>8.3 mV

<0.5 mV

Right

Ventricle

RAO

Left lateral

projection

Right

Ventricle

Right

Ventricle

Right

Ventricle

PV

PV

PV

TV

TV TV

LAO

Bipolar Unipolar

KHRS Scientific Sessions 2018, Seoul8 June 2018 28

Page 29: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

Right

Ventricle

Left lateral

projection

PV

TV

Entrance site:

ECF; PPI=TCL;

long S-QRS =

egm-QRS

Exit site:

ECF; PPI=TCL;

short S-QRS =

egm-QRS

VT 2:

clinical VT

KHRS Scientific Sessions 2018, Seoul8 June 2018 29

Page 30: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

Termination in 9 seconds with RF

KHRS Scientific Sessions 2018, Seoul8 June 2018 30

Page 31: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

>1.0 mV

<0.5 mV

LAO

cranial

Base

Apex

MAP d

MAP p

RV

epicardiumLV

epicardium

LAO

RAO

RV endocardial

catheter

Epicardial

catheter

RV endocardial

catheter

Epicardial

catheter

KHRS Scientific Sessions 2018, Seoul8 June 2018 31

Page 32: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

Extensive substrate ablation for

other unmappable morphologies

… but still inducible for 2 nonclinical VTs at case end

KHRS Scientific Sessions 2018, Seoul8 June 2018 32

Page 33: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

KHRS Scientific Sessions 2018, Seoul8 June 2018 33Kumar et. al. Circ AE 2015

n=21 patients

with cardiac

sarcoid and

VT catheter

ablation

Page 34: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

KHRS Scientific Sessions 2018, Seoul8 June 2018 34Kumar et. al. Circ AE 2015

Page 35: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

KHRS Scientific Sessions 2018, Seoul8 June 2018 35Kumar et. al. Circ AE 2016

n=25 patients

with cardiac

LMNA and

VT catheter

ablation

Page 36: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

KHRS Scientific Sessions 2018, Seoul8 June 2018 36Kumar et. al. Circ AE 2016

Page 37: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

KHRS Scientific Sessions 2018, Seoul8 June 2018 37Kumar et. al. Circ AE 2016

Page 38: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

KHRS Scientific Sessions 2018, Seoul8 June 2018 38Ollila et. al. Open Heart 2017

Page 39: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

Clear association

with outcome

Oloriz et. al. Circ A&E 2014KHRS Scientific Sessions 2018, Seoul8 June 2018 39

Page 40: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

Conclusions

• Basal septal substrate represents an important pattern

of involvement in NICM and frequently has a substantial

intramural component

• Bipolar endo-epicardial voltage mapping may be

entirely normal in these patients

• NICM septal substrate may affect the sinus rhythm ECG

with a high prevalence of conduction system disease

and leads to characteristic septal VT morphologies

• Multimodality imaging is an important diagnostic

modality for defining septal involvement

• This group of patients has a worse prognosis than the

basolateral group and ablation is challenging

KHRS Scientific Sessions 2018, Seoul8 June 2018 40

Page 41: Ablation of Ventricular Tachycardia in Nonischemic ...k-hrs.org/KHRS/2018/pdf/3. Haris Haqqani.pdf · Cardiogenic shock 1 Late outcomes n = 31 Median follow up 12 mo VT recurrence

KHRS Scientific Sessions 2018, Seoul8 June 2018 41